Located in the nucleus and in the cytoplasm, CapG has also been identified as an oncogene, and its overexpression has been associated with poor prognosis and metastasis in several cancers including BC, colorectal, and prostate cancer [44,45]. Here, CAPG is linked to breast cancer.